Cassady Schiller Wealth Management LLC Has $508,000 Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cassady Schiller Wealth Management LLC trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,506 shares of the medical equipment provider’s stock after selling 64 shares during the quarter. Cassady Schiller Wealth Management LLC’s holdings in Intuitive Surgical were worth $508,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ISRG. Baystate Wealth Management LLC boosted its stake in Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares in the last quarter. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares during the last quarter. Headinvest LLC bought a new stake in Intuitive Surgical during the third quarter worth $28,000. Stone House Investment Management LLC grew its stake in shares of Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 50 shares in the last quarter. Finally, Truvestments Capital LLC increased its stake in Intuitive Surgical by 137.2% in the 3rd quarter. Truvestments Capital LLC now owns 102 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 59 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of a number of recent analyst reports. Raymond James lifted their target price on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Truist Financial upped their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. BTIG Research lifted their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Finally, Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Trading Down 1.0 %

Shares of ISRG stock traded down $4.03 during trading hours on Thursday, hitting $396.87. 685,053 shares of the company’s stock were exchanged, compared to its average volume of 1,536,141. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $408.43. The company has a market capitalization of $140.77 billion, a PE ratio of 72.36, a PEG ratio of 5.19 and a beta of 1.39. The business’s 50 day simple moving average is $386.00 and its 200-day simple moving average is $360.92.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. Equities analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total transaction of $67,763.50. Following the transaction, the senior vice president now owns 533 shares in the company, valued at approximately $206,388.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total transaction of $67,763.50. Following the completion of the transaction, the senior vice president now owns 533 shares in the company, valued at $206,388.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The disclosure for this sale can be found here. Insiders sold 148,290 shares of company stock valued at $57,207,154 in the last 90 days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.